| Stacy Arnold |
Stacy Arnold is currently working as the VP-Product Development & Clinical Research at Axogen, Inc. Prior to this, Stacy worked at Artivion, Inc. as the Senior Director-Research & Development from 2006 to 2018. Stacy completed their undergraduate degree at Mercer University and their graduate degree at the University of Toledo (Ohio). |
| Erick Wayne DeVinney |
Erick Wayne DeVinney is currently the Director at Global Nerve Foundation since 2022 and the Chief Innovation Officer at Axogen, Inc. since 2007. Previously, he worked as the Director-Clinical & Translational Sciences at AxoGen Corp. from 2007 to 2014 and as the Manager-Clinical Operations at Angiotech Pharmaceuticals, Inc. from 2005 to 2007. He also held positions as Principal at National Clinical Research Centers, Inc. and Medical College of Virginia. Mr. DeVinney completed his undergraduate degree at Virginia Commonwealth University in 2000. |
| Marc A. Began |
Marc A. Began is currently the Chief Compliance Officer, EVP & General Counsel at Axogen, Inc. Prior to his current position, he served as the Secretary, Vice President & General Counsel at ABIOMED, Inc. from 2018 to 2022. Marc also worked as an Associate at White & Case LLP and Sullivan & Cromwell LLP. He held the position of Vice President-Intellectual Property at Boehringer Ingelheim Corp. and Assistant General Counsel at Novo Nordisk, Inc. Mr. Began completed his undergraduate degree at Rensselaer Polytechnic Institute and his graduate degree at Albany Law School. |
| Ivica Ducic |
Ivica Ducic is currently the Chief Medical Officer at Axogen, Inc. He previously worked as a Professor of Plastic Surgery & Neurosurgery at Georgetown University Hospital, President of the American Society for Peripheral Nerve, and Clinical Professor of Surgery at George Washington University. He obtained his doctorate degree from the University of Zagreb School of Medicine in 1995. |
| Karen L. Zaderej |
Karen L. Zaderej is the founder of Zaderej Medical Consulting, which was founded in 2004. She is currently the Chairman, President & Chief Executive Officer of Axogen, Inc. since 2018. She is also a Director at Viveve, Inc. since 2018 and an Independent Director at EyePoint Pharmaceuticals, Inc. since 2022. Additionally, she serves as a Director at Southeast BIO and as a Trustee at The University of Tampa, Inc. In her former positions, she was the Chief Executive Officer of LecTec Corp. in 2011, the Chief Executive Officer & Director of AxoGen Corp. from 2006 to 2014, and an Independent Director at Viveve Medical, Inc. from 2018 to 2020. She also worked at Johnson & Johnson as a Principal. Ms. Zaderej completed her undergraduate degree at Purdue University and holds an MBA from Kellogg School of Management. |
| Nir Naor |
Nir Naor is an Independent Director at Brainstorm Cell Therapeutics, Inc. and the Chief Financial Officer at Axogen, Inc. He previously worked as an Auditor at KPMG Corporate Finance LLC from 2001 to 2005. From 2012 to 2017, he served as the Chief Financial Officer-United States at UCB SA. In 2021, he briefly held the position of Chief Financial Officer at Arbor Pharmaceuticals, Inc. From 2017 to 2021, he was the Chief Financial Officer-US Americas at Molnlycke Health Care US LLC. Mr. Naor completed his undergraduate and graduate degrees at Tel-Aviv University and also holds a graduate degree from the University of Hamburg. He further obtained an MBA from the International Institute for Management Development. |
| Jens Schroeder Kemp |
Jens Schroeder Kemp was the founder of Mindgroup ApS, a company founded in 2001, where he held the title of Manager-Sales & Marketing from 2001 to 2003. He is currently the Chief Marketing Officer at Axogen, Inc. since 2023. In his former positions, he worked as Vice President-Marketing at Ambu, Inc. and as Manager-Corporate Business Development at Ambu A from 2006 to 2013. Mr. Kemp has an educational background, having studied at Copenhagen Business School, where he completed both undergraduate and graduate degrees. |
| Joseph Adrian Tyndall |
Joseph Adrian Tyndall is currently the Chairman at Uf Health Proton Therapy Institute and the Director at Grady Health System, Inc. He is also an Independent Director at Axogen, Inc. since 2022. In addition, he is the Executive VP-Health Affairs & Professor at Morehouse School of Medicine since 2021. He is a former Director at Shands Teaching Hospitals & Clinics, Inc. from 2010 to 2021 and a former Director at Florida College of Emergency Physicians from 2011 to 2021. He has also held the position of Chief Resident at University of Maryland Medical System Corp. He is a Professor at the University of Florida College of Medicine and an Associate Vice President-Strategic at University of Florida Health Network. He is a Member of Alpha Omega Alpha Honor Medical Society and The Gold Humanism Honor Society. He has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Maryland School of Medicine. |
| William Patrick Burke |
William Patrick Burke is currently the Chairman at Haemonetics SA and Co-Managing Director at Haemonetics GmbH. He is also an Independent Director at Axogen, Inc. since 2022 and a Director at Haemonetics Ltd. since 2016. Previously, he served as Chairman at Inlog Holdings France SASU, Managing Director at Covidien Group SARL (Switzerland), CFO-Europe & Vice President-Corporate Strategy at Covidien LP, and CFO-Europe & Vice President-Corporate Strategy at Covidien Unlimited Co. from 2008 to 2014. He was also the Chief Integration Officer at Medtronic Plc from 2014 to 2016. Additionally, he served as an Independent Director at Miromatrix Medical, Inc. from 2021 to 2023 and as an Auditor at KPMG LLP. He started his career as a Financial Controller at Valleylab, Inc. He received his undergraduate degree from Bryant University in 1990. |
| Amy A. McBride-Wendell |
Amy A. McBride-Wendell is currently serving as the Chairman at Por Christo. She is also an Independent Director at Baxter International, Inc., Hologic, Inc., Ekso Bionics, Inc., Lead Independent Director at Axogen, Inc., and Director at Baxter Healthcare Ltd. (United Kingdom). In her former positions, Ms. McBride-Wendell served as an Independent Non-Employee Director at Ekso Bionics Holdings, Inc. from 2015 to 2018. She was the Vice President-Business Development & Licensing at Covidien LP from 2006 to 2015. She also held the position of SVP-Strategy & Business Development at Covidien New Zealand Ltd. from 1998 to 2007 and VP-Strategy, Business Development & Licensing at Covidien Unlimited Co. from 1986 to 2015. Additionally, she was the VP-Tyco Healthcare Business Development at Kendall Healthcare Products. Ms. McBride-Wendell was the Senior Vice President-Strategy at Medtronic Plc from 2006 to 2015. Ms. McBride-Wendell completed her undergraduate degree at Lawrence Technological University in 1983. She then pursued her graduate degree at the University of Illinois, which she completed in 1986. |
| John H. Johnson |
John joined HealthQuest in 2023 as an Operating Partner focused on the Tactical Opportunities Fund. John is a recognized leader in the healthcare industry with more than three decades of experience across operating and investing. He is currently Chief Executive Officer at Reaction Biology, a global CRO. He previously was the Chief Executive Officer of Strongbridge Biopharma PLC. prior to the merger with Xeris Biopharma. John has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of career and served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson. He was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. John also served as President of Eli Lilly & Company's Worldwide Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as Chief Executive Officer and a member of ImClone’s Board of Directors.
John has served on 18 boards and presently serves on 5 company boards including Reaction Biology, Axogen (AXGN), Xeris Pharmaceuticals (XERS), Verastem Oncology (VSTM) and Autolus Ltd (AUTL). He served on two private equity backed company boards through successful exits, including most recently BioAgilytix and W2O. He has also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). John received his BS from East Stroudsburg University and MBA from University of Rochester, Simon Business School. John and his wife have 4 children and 4 grandchildren. In his free time, he enjoys golf, fishing, and archery. |
| Guido J. Neels |
Guido Neels joined EW in 2006 and transitioned to an Operating Partner in 2013.
Mr. Neels has played a key role in building and leading EW’s medical device investment practice. He currently serves on the Board of Directors of EW growth equity portfolio companies Enercoon Technologies, AxoGen, and Bioventus.
Prior to joining EW, Mr. Neels served as Chief Operating Officer of Guidant Corporation. Mr. Neels was responsible for the operations of Guidant’s four operating units, Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. Previously he was responsible for sales operations, corporate communications, corporate marketing, investor relations and government relations. He also served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. Prior to joining Guidant, Mr. Neels held general management, sales and marketing positions at Eli Lilly & Company in the U.S. and Europe.
Mr. Neels holds a Business Engineering degree from the University of Leuven in Belgium and a Master of Business Administration degree from Stanford University. |
| Alan M. Levine |
Mr. Alan M. Levine is an Independent Director at United Homes Group, Inc., an Independent Director at Axogen, Inc., a Chairman, President & Chief Executive Officer at Mountain States Health Alliance and an Executive Chairman, President & CEO at Ballad Health. He is on the Board of Directors at United Homes Group, Inc., Axogen, Inc., Niswonger Foundation, H. Lee Moffitt Cancer Center & Research Institute, Inc. and State University System of Florida (Florida). Mr. Levine was previously employed as a Senior Vice President & President-Florida Group by Health Management Associates, Inc., a Secretary by Louisiana Department of Health & Hospitals (Louisiana), a President & Chief Executive Officer by North Broward Hospital District (Florida), a Secretary by Florida Agency for Health Care Administration (United States), a President & General Manage by South Florida Group Realty, Inc., and a Chairman-Higher Education Coordinating Council by State of Florida. He also served on the board at Barbara Bush Foundation for Family Literacy. He received his undergraduate degree from the University of Florida, a graduate degree from the University of Florida and an MBA from the University of Florida. |
| Paul G. Thomas |
Paul G. Thomas founded Sorrento Tech, Inc. in 2009, where he worked as President, Chief Executive Officer & Director from 2009 to 2017, Prominex, Inc. in 2018, where he worked as Chief Executive Officer, Prominex, Inc. (California) in 2018, where he is working as Chief Executive Officer & Director from 2018, and Roka Bioscience, Inc. in 2009, where he is working as Director from 2017. Mr. Thomas also currently works at Biotechnology Innovation Organization, as Director, Surgalign Spine Technologies, Inc., as Director from 2016, and Axogen, Inc., as Independent Director from 2020. Mr. Thomas also formerly worked at LifeCell Corp., as Chairman, President & Chief Executive Officer from 1998 to 2008, New England Healthcare Institute, as Chairman, ABIOMED, Inc., as Independent Director from 2011 to 2022, Orthovita, Inc., as Director from 2007 to 2011, Genzyme Corp., as President & Director, Innovative Spinal Technologies, Inc., as Director from 2006 to 2009, Aegerion Pharmaceuticals, Inc., as Independent Director from 2011 to 2016, Cohera Medical, Inc., as Director, Pharmaceutical Research & Manufacturers of America, as Director, Surgalign Holdings, Inc., as Independent Director from 2016 to 2023, Hambrecht & Quist Healthcare Investors, as Trustee, Ohmeda, Inc., as President-Pharmaceutical Products Division from 1982 to 1998, and Ohmeda Medical, Inc., as President-Pharmaceutical Products. Mr. Thomas received his undergraduate degree in 1977 from St. Michael's College, Masters Business Admin degree in 1982 from Columbia Business School, and graduate degree from Graduate School of Georgia University. |
